Mendus

.Hero-module--bg-image--629a6:before { opacity: 1; background-image: url('/static/e62925564ecb1ec6ce1d956cde68e06b/44759/2026-granddad-child-reading-landscape-1-scaled.jpg'); }

Att förändra hur cancer behandlasVi utforskar hur kraften i kroppens immunsystem kan användas för att förbättra långtidsöverlevnaden för cancerpatienter, samtidigt som hälsan och livskvaliteten bevaras.
Om oss
<picture><source type="image/webp" srcSet="/static/cbef2250e4b1091904db21cbb1041448/9e9c6/Screenshot-2026-06-25-145340-e1782976184412.webp 175w,/static/cbef2250e4b1091904db21cbb1041448/f73d4/Screenshot-2026-06-25-145340-e1782976184412.webp 350w,/static/cbef2250e4b1091904db21cbb1041448/af869/Screenshot-2026-06-25-145340-e1782976184412.webp 700w" sizes="(min-width: 700px) 700px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 700px) 700px, 100vw" decoding="async" loading="lazy" src="/static/cbef2250e4b1091904db21cbb1041448/04bdd/Screenshot-2026-06-25-145340-e1782976184412.png" srcSet="/static/cbef2250e4b1091904db21cbb1041448/7b980/Screenshot-2026-06-25-145340-e1782976184412.png 175w,/static/cbef2250e4b1091904db21cbb1041448/80765/Screenshot-2026-06-25-145340-e1782976184412.png 350w,/static/cbef2250e4b1091904db21cbb1041448/04bdd/Screenshot-2026-06-25-145340-e1782976184412.png 700w" alt=""/></picture>
Mendus presenterar data om vididencel vid högriskäggstockscancerLäs mer
<picture><source type="image/webp" srcSet="/static/4500665f26ce306f14cdb18f8de4615d/bde29/061008-Hans-COO-1.webp 227w,/static/4500665f26ce306f14cdb18f8de4615d/58906/061008-Hans-COO-1.webp 454w,/static/4500665f26ce306f14cdb18f8de4615d/b7017/061008-Hans-COO-1.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/4500665f26ce306f14cdb18f8de4615d/b4646/061008-Hans-COO-1.jpg" srcSet="/static/4500665f26ce306f14cdb18f8de4615d/1c00b/061008-Hans-COO-1.jpg 227w,/static/4500665f26ce306f14cdb18f8de4615d/e7daf/061008-Hans-COO-1.jpg 454w,/static/4500665f26ce306f14cdb18f8de4615d/b4646/061008-Hans-COO-1.jpg 907w" alt=""/></picture>
Hans Preusting utnämnd COOLäs hela press releasen
<picture><source type="image/webp" srcSet="/static/68f26fe34509e1e6556b7b770d71a6ed/bde29/260911-VITAL-CML-stage-1-WEBSITE-1.webp 227w,/static/68f26fe34509e1e6556b7b770d71a6ed/58906/260911-VITAL-CML-stage-1-WEBSITE-1.webp 454w,/static/68f26fe34509e1e6556b7b770d71a6ed/b7017/260911-VITAL-CML-stage-1-WEBSITE-1.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/68f26fe34509e1e6556b7b770d71a6ed/b4646/260911-VITAL-CML-stage-1-WEBSITE-1.jpg" srcSet="/static/68f26fe34509e1e6556b7b770d71a6ed/1c00b/260911-VITAL-CML-stage-1-WEBSITE-1.jpg 227w,/static/68f26fe34509e1e6556b7b770d71a6ed/e7daf/260911-VITAL-CML-stage-1-WEBSITE-1.jpg 454w,/static/68f26fe34509e1e6556b7b770d71a6ed/b4646/260911-VITAL-CML-stage-1-WEBSITE-1.jpg 907w" alt=""/></picture>
Positiva resultat från VITAL-CML-studien stöder KML programmetLäs mer
<picture><source type="image/webp" srcSet="/static/ab091f0d621005acb04361459d7af797/bde29/260716-Mendus-Q2-INTERIM-REPORT-WEBSITE-1.webp 227w,/static/ab091f0d621005acb04361459d7af797/58906/260716-Mendus-Q2-INTERIM-REPORT-WEBSITE-1.webp 454w,/static/ab091f0d621005acb04361459d7af797/b7017/260716-Mendus-Q2-INTERIM-REPORT-WEBSITE-1.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/ab091f0d621005acb04361459d7af797/b4646/260716-Mendus-Q2-INTERIM-REPORT-WEBSITE-1.jpg" srcSet="/static/ab091f0d621005acb04361459d7af797/1c00b/260716-Mendus-Q2-INTERIM-REPORT-WEBSITE-1.jpg 227w,/static/ab091f0d621005acb04361459d7af797/e7daf/260716-Mendus-Q2-INTERIM-REPORT-WEBSITE-1.jpg 454w,/static/ab091f0d621005acb04361459d7af797/b4646/260716-Mendus-Q2-INTERIM-REPORT-WEBSITE-1.jpg 907w" alt=""/></picture>
Mendus publicerar andra kvartalsrapporten 2026Läs hela pressreleasen här
<picture><source type="image/webp" srcSet="/static/733f50bbc0e2fdc1ab5eff8741149228/bde29/260716-Mendus-SAHMRI-WEBSITE-1.webp 227w,/static/733f50bbc0e2fdc1ab5eff8741149228/58906/260716-Mendus-SAHMRI-WEBSITE-1.webp 454w,/static/733f50bbc0e2fdc1ab5eff8741149228/b7017/260716-Mendus-SAHMRI-WEBSITE-1.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/733f50bbc0e2fdc1ab5eff8741149228/b4646/260716-Mendus-SAHMRI-WEBSITE-1.jpg" srcSet="/static/733f50bbc0e2fdc1ab5eff8741149228/1c00b/260716-Mendus-SAHMRI-WEBSITE-1.jpg 227w,/static/733f50bbc0e2fdc1ab5eff8741149228/e7daf/260716-Mendus-SAHMRI-WEBSITE-1.jpg 454w,/static/733f50bbc0e2fdc1ab5eff8741149228/b4646/260716-Mendus-SAHMRI-WEBSITE-1.jpg 907w" alt=""/></picture>
Mendus samarbetar med SAHMRI i förberedelse för VITAL-TFR2 studienLäs mer här
<picture><source type="image/webp" srcSet="/static/cbef2250e4b1091904db21cbb1041448/9e9c6/Screenshot-2026-06-25-145340-e1782976184412.webp 175w,/static/cbef2250e4b1091904db21cbb1041448/f73d4/Screenshot-2026-06-25-145340-e1782976184412.webp 350w,/static/cbef2250e4b1091904db21cbb1041448/af869/Screenshot-2026-06-25-145340-e1782976184412.webp 700w" sizes="(min-width: 700px) 700px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 700px) 700px, 100vw" decoding="async" loading="lazy" src="/static/cbef2250e4b1091904db21cbb1041448/04bdd/Screenshot-2026-06-25-145340-e1782976184412.png" srcSet="/static/cbef2250e4b1091904db21cbb1041448/7b980/Screenshot-2026-06-25-145340-e1782976184412.png 175w,/static/cbef2250e4b1091904db21cbb1041448/80765/Screenshot-2026-06-25-145340-e1782976184412.png 350w,/static/cbef2250e4b1091904db21cbb1041448/04bdd/Screenshot-2026-06-25-145340-e1782976184412.png 700w" alt=""/></picture>
Mendus presenterar data om vididencel vid högriskäggstockscancerLäs mer
<picture><source type="image/webp" srcSet="/static/4500665f26ce306f14cdb18f8de4615d/bde29/061008-Hans-COO-1.webp 227w,/static/4500665f26ce306f14cdb18f8de4615d/58906/061008-Hans-COO-1.webp 454w,/static/4500665f26ce306f14cdb18f8de4615d/b7017/061008-Hans-COO-1.webp 907w" sizes="(min-width: 907px) 907px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 907px) 907px, 100vw" decoding="async" loading="lazy" src="/static/4500665f26ce306f14cdb18f8de4615d/b4646/061008-Hans-COO-1.jpg" srcSet="/static/4500665f26ce306f14cdb18f8de4615d/1c00b/061008-Hans-COO-1.jpg 227w,/static/4500665f26ce306f14cdb18f8de4615d/e7daf/061008-Hans-COO-1.jpg 454w,/static/4500665f26ce306f14cdb18f8de4615d/b4646/061008-Hans-COO-1.jpg 907w" alt=""/></picture>
Hans Preusting utnämnd COOLäs hela press releasen

<picture><source type="image/webp" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/d7070/Startpage_1-NEW.webp 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/4ce17/Startpage_1-NEW.webp 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/95cd0/Startpage_1-NEW.webp 960w" sizes="(min-width: 960px) 960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 960px) 960px, 100vw" decoding="async" loading="lazy" src="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW.jpg" srcSet="/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/ff13b/Startpage_1-NEW.jpg 240w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/28e6b/Startpage_1-NEW.jpg 480w,/static/8fbb9182e4eaf95a3da736b2a3ebdc7e/49439/Startpage_1-NEW.jpg 960w" alt=""/></picture>
Att få övertagetIdag är återkommande tumörer den främsta orsaken till cancerrelaterade dödsfall. Vi strävar efter att minska tumöråterfall genom att utnyttja immunsystemet för att agera mot kvarvarande cancerceller.
Hur vi gör

<picture><source type="image/webp" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8cdf4/Startpage_3-1.webp 302w,/static/0237bef387e76cffaa6681d16a2b59c4/39272/Startpage_3-1.webp 603w,/static/0237bef387e76cffaa6681d16a2b59c4/0d01b/Startpage_3-1.webp 1206w" sizes="(min-width: 1206px) 1206px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 1206px) 1206px, 100vw" decoding="async" loading="lazy" src="/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3-1.jpg" srcSet="/static/0237bef387e76cffaa6681d16a2b59c4/8f82e/Startpage_3-1.jpg 302w,/static/0237bef387e76cffaa6681d16a2b59c4/d2caf/Startpage_3-1.jpg 603w,/static/0237bef387e76cffaa6681d16a2b59c4/e579d/Startpage_3-1.jpg 1206w" alt="&lt;p&gt;Molecular Structure. Science background. 3D Render&lt;/p&gt;
"/></picture>
Investera i framtidens cancervårdMendus är noterat på NASDAQ Stockholm under tickersymbolen IMMU. Du hittar all relevant information om Mendus-aktien på vår investerarsida.
Investerare

Senaste nyheternaNyheter och Evenemang
Inga hittade artiklar

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89:before { opacity: 1; background-image: url('/static/58920a993c01776af52e6d8a69a7452d/60e72/What-we-do_1-mobile.jpg'); }

Hur vi gör